文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

嵌合抗原受体T细胞(CAR T细胞)生产监测解决方案分析

An Analysis of Monitoring Solutions for CAR T Cell Production.

作者信息

Shoshi Arber, Xia Yuchen, Fieschi Andrea, Baumgarten Yannick, Gaißler Andrea, Ackermann Thomas, Reimann Peter, Mitschang Bernhard, Weyrich Michael, Bauernhansl Thomas, Miehe Robert

机构信息

Graduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.

Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) Stuttgart Germany.

出版信息

Healthc Technol Lett. 2025 May 13;12(1):e70012. doi: 10.1049/htl2.70012. eCollection 2025 Jan-Dec.


DOI:10.1049/htl2.70012
PMID:40365510
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12073936/
Abstract

The chimeric antigen receptor T cell (CAR T) therapy has shown remarkable results in treating certain cancers. It involves genetically modifying a patient's T cells to recognize and attack cancer cells. Despite its potential, CAR T cell therapy is complex and costly and requires the integration of multiple technologies and specialized equipment. Further research is needed to achieve the maximum potential of CAR T cell therapies and to develop effective and efficient methods for their production. This paper presents an overview of current measurement methods used in the key steps of the production of CAR T cells. The study aims to assess the state of the art in monitoring solutions and identify their potential for online monitoring. The results of this paper contribute to the understanding of measurement methods in CAR T cell manufacturing and identify areas where on-line monitoring can be improved. Thus, this research facilitates progress toward the development of effective monitoring of CAR T cell therapies.

摘要

嵌合抗原受体T细胞(CAR T)疗法在治疗某些癌症方面已显示出显著效果。它涉及对患者的T细胞进行基因改造,使其能够识别并攻击癌细胞。尽管CAR T细胞疗法具有潜力,但它复杂且成本高昂,需要整合多种技术和专业设备。为了充分发挥CAR T细胞疗法的最大潜力并开发有效且高效的生产方法,还需要进一步研究。本文概述了CAR T细胞生产关键步骤中使用的当前测量方法。该研究旨在评估监测解决方案的技术现状,并确定其在线监测的潜力。本文的结果有助于理解CAR T细胞制造中的测量方法,并确定可改进在线监测的领域。因此,这项研究促进了朝着有效监测CAR T细胞疗法发展的进程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/9946d6b35d3c/HTL2-12-e70012-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/d20ffcc7ec1a/HTL2-12-e70012-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/8361b9088b93/HTL2-12-e70012-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/9946d6b35d3c/HTL2-12-e70012-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/d20ffcc7ec1a/HTL2-12-e70012-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/8361b9088b93/HTL2-12-e70012-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/12073936/9946d6b35d3c/HTL2-12-e70012-g004.jpg

相似文献

[1]
An Analysis of Monitoring Solutions for CAR T Cell Production.

Healthc Technol Lett. 2025-5-13

[2]
[CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].

Internist (Berl). 2021-4

[3]
Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group.

Bone Marrow Transplant. 2023-10

[4]
Better by design: What to expect from novel CAR-engineered cell therapies?

Biotechnol Adv. 2022-9

[5]
Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.

Int J Mol Sci. 2024-9-26

[6]
CAR-T cell therapies: patient access and affordability solutions.

Future Sci OA. 2025-12

[7]
Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing.

Front Mol Med. 2023-9-21

[8]
Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.

Exp Hematol Oncol. 2023-8-21

[9]
How can Cytokine-induced killer cells overcome CAR-T cell limits.

Front Immunol. 2023

[10]
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.

Med Oncol. 2023-8-22

本文引用的文献

[1]
Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance.

Eur J Pharm Sci. 2024-12-1

[2]
Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies.

Cancers (Basel). 2024-9-29

[3]
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.

Clin Cancer Res. 2024-10-15

[4]
The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy.

Blood Cancer Discov. 2024-7-1

[5]
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.

Front Immunol. 2024

[6]
Smart Sensor Control and Monitoring of an Automated Cell Expansion Process.

Sensors (Basel). 2023-12-7

[7]
Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform.

Cytotherapy. 2023-12

[8]
Detection and quantification of integrated vector copy number by multiplex droplet digital PCR in dual-transduced CAR T cells.

Mol Ther Methods Clin Dev. 2023-7-15

[9]
A disposable impedance-based sensor for in-line cell growth monitoring in CAR-T cell manufacturing.

Bioelectrochemistry. 2023-8

[10]
Off-target effects in CRISPR/Cas9 gene editing.

Front Bioeng Biotechnol. 2023-3-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索